Completed

Genetics of Rheumatoid Arthritis: The North American Rheumatoid Arthritis Consortium

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Who is being recruted

Arthritis+6

+ Connective Tissue Diseases

+ Immune System Diseases

Over 18 Years
See all eligibility criteria
How is the trial designed

Observational
Study Start: July 1998
See protocol details

Summary

Principal SponsorNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Last updated: October 6, 2017
Sourced from a government-validated database.Claim as a partner

Study start date: July 7, 1998

Actual date on which the first participant was enrolled.

The purpose of this protocol is to identify genetic susceptibility loci for rheumatoid arthritis. The Genetics and Genomics Branch of the Intramural Research Program of NIAMS [now the Inflammatory Diseases Section of the Intramural Research Program of NHGRI] has joined with several extramural centers to form the North American Rheumatoid Arthritis Consortium (NARAC). The Consortium intends to identify and obtain clinical specimens on a total of 1000 sibling pairs with rheumatoid arthritis; up to 100 sibling pairs will be recruited at the Clinical Center. Samples from parents and other family members will also be obtained, where appropriate. Rheumatoid factors, HLA-DR typings, and hand films will be obtained on all sibling pairs. In addition, DNA will be extracted from peripheral blood or buccal scrapings. The DNA from all 1000 sibling pairs will be typed for a set of approximately 350 genetic markers in order to identify chromosomal regions likely to harbor genes conferring susceptibility to rheumatoid arthritis. For those chromosomal regions that are positive in this initial screen, families will be genotyped for additional markers to define disease-associated haplotypes, and high density single nucleotide polymorphism (SNP) analysis will be conducted to narrow the regions of interest. Candidate genes will be chosen from the narrowed regions of interest, and/or based on functional considerations, and will be screened for mutations in rheumatoid arthritis.

NCT00001678
Principal SponsorNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Last updated: October 6, 2017
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

39 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

ArthritisConnective Tissue DiseasesImmune System DiseasesJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesSkin and Connective Tissue DiseasesArthritis, RheumatoidAutoimmune Diseases

Criteria

INCLUSION CRITERIA: SIBLING PAIR: A diagnosis of rheumatoid arthritis in both sibs by the 1987 ACR criteria. Definite bony erosions in at least one affected sibling. Age of disease onset greater than 18 years and less than 60 years in at least one sibling. Neither sibling has psoriasis, inflammatory bowel disease, or systemic lupus erythematosus. BLOOD RELATIVES OF AFFECTED SIBLING PAIRS: Age greater than 18 years. Where possible, all other affected siblings will be invited to participate. Where possible, both parents of affected siblings will be invited to participate. Other relatives, both affected and unaffected, may be invited to participate if, in the opinion of the investigators, samples from these individuals would contribute important genetic information. Two cases in which this might happen are: a) extended families in which there are several affected individuals, where conventional linkage analysis might be applied; b) affected sibling pairs for which parents are unavailable, where additional siblings will provide information on parental alleles not transmitted to the affected siblings. EXCLUSION CRITERIA FOR AFFECTED SIBLINGS: Psoriasis, inflammatory bowel disease, systemic lupus erythematosus. Inability to provide infomed consent. The sole criterion for exclusion of adult blood relatives of affected sibling pairs would be inability to provide informed consent.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, United StatesOpen National Institutes of Health Clinical Center, 9000 Rockville Pike in Google Maps
CompletedOne Study Center